Literature DB >> 19896845

Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.

David J Richard1, Jeroen C Verheijen, Kevin Curran, Joshua Kaplan, Lourdes Toral-Barza, Irwin Hollander, Judy Lucas, Ker Yu, Arie Zask.   

Abstract

A series of highly potent and selective pyrazolopyrimidine mTOR inhibitors which contain water-solubilizing groups attached to the 6-arylureidophenyl moiety have been prepared. Such derivatives displayed superior potency to those in which these appendages were attached to alternative sites. In comparison to unfunctionalized arylureido compounds, these analogs demonstrated enhanced cellular potency and significantly improved stability towards human microsomes, resulting in an mTOR inhibitor with impressive efficacy in a xenograft model with an intermittent dosing regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896845     DOI: 10.1016/j.bmcl.2009.10.096

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  mTOR Mediated Anti-Cancer Drug Discovery.

Authors:  Qingsong Liu; Carson Thoreen; Jinhua Wang; David Sabatini; Nathanael S Gray
Journal:  Drug Discov Today Ther Strateg       Date:  2009

2.  Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

Authors:  Qingsong Liu; Jae Won Chang; Jinhua Wang; Seong A Kang; Carson C Thoreen; Andrew Markhard; Wooyoung Hur; Jianming Zhang; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

3.  Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.

Authors:  Qingsong Liu; Jinhua Wang; Seong A Kang; Carson C Thoreen; Wooyoung Hur; Hwan Geun Choi; David L Waller; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2011-05-07       Impact factor: 2.823

4.  Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Authors:  Qingsong Liu; Jinhua Wang; Seong A Kang; Carson C Thoreen; Wooyoung Hur; Tausif Ahmed; David M Sabatini; Nathanael S Gray
Journal:  J Med Chem       Date:  2011-02-15       Impact factor: 7.446

5.  A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR.

Authors:  Ting Ran; Tao Lu; Haoliang Yuan; Haichun Liu; Jian Wang; Weiwei Zhang; Ying Leng; Guowu Lin; Shulin Zhuang; Yadong Chen
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

Review 6.  Chemical and Structural Strategies to Selectively Target mTOR Kinase.

Authors:  Chiara Borsari; Martina De Pascale; Matthias P Wymann
Journal:  ChemMedChem       Date:  2021-07-01       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.